ERBB2 and breast carcinoma: Breast cancer is the most frequently diagnosed cancer and is the second leading cause of cancer death among females.[1, 2] Despite advances in detection and treatment, 20-30% of patients with early-stage breast cancer will become metastatic.[3] The development of targeted therapy for HR-positive and HER2-overexpressing MBC has significantly improved outcomes in these subsets.[4-9] However, upon development of resistance to these therapies and in the setting of TNBC, cytotoxic chemotherapy remains the backbone of treatment, and long-term outcomes remain poor.[10]